Exelixis, Inc. filed a Form 8-K on September 11, 2026, disclosing that the FDA extended the review period for its new drug application for zanzalintinib in combination with atezolizumab by three months, moving the action date to March 3, 2027.
Key Highlights
- FDA review extended: The FDA extended the NDA review period for zanzalintinib, in combination with atezolizumab, by three months.
- Indication: The NDA targets treatment of patients with metastatic colorectal cancer.
- Reason for extension: Exelixis submitted updated safety and efficacy data in response to an FDA information request, which the FDA deemed a major amendment.
- New action date: The updated Prescription Drug User Fee Act action date is March 3, 2027.
- Event date: The FDA notification was received on September 10, 2026.
FDA Deems Exelixis Data Submission a Major Amendment, Extending Zanzalintinib NDA Review
According to the filing, Exelixis, Inc. (NASDAQ:EXEL) disclosed on September 11, 2026, that the U.S. Food and Drug Administration notified the company on September 10, 2026, that it had extended the review period for Exelixis' new drug application for zanzalintinib, in combination with atezolizumab, for the treatment of patients with metastatic colorectal cancer. The extension is for three months.
The filing states that the extension was triggered by Exelixis submitting updated safety and efficacy data in response to an FDA information request. The FDA classified this submission as a major amendment, which the agency cited as the basis for the extended review period. The company reported that the updated Prescription Drug User Fee Act action date is now March 3, 2027.
The 8-K was filed under Item 8.01 (Other Events) and was signed by Brenda J. Hefti, Senior Vice President and General Counsel of Exelixis, Inc. The company's common stock, with a par value of $0.001 per share, is listed on The Nasdaq Stock Market LLC under the trading symbol EXEL.
What Was Disclosed
Exelixis disclosed that the FDA extended its NDA review for zanzalintinib combined with atezolizumab in metastatic colorectal cancer by three months, following updated safety and efficacy data the FDA classified as a major amendment, with a new action date of March 3, 2027.




Please wait processing your request...